Skip to main content
. 2020 Mar 4;11(4):935–942. doi: 10.1111/1759-7714.13378

Figure 2.

Figure 2

Kaplan‐Meier curves for progression‐free survival (PFS) in the patients who received (a) osimertinib as second‐line or third‐/later‐line (Inline graphic) second‐line (n = 19), and (Inline graphic) third‐/later‐line (n = 37) and (b) osimertinib as second‐line or fourth‐/later‐line (Inline graphic) second‐line (n = 19), and (Inline graphic) fourth‐/later‐line (n = 22).